 |
0 Diseases |  |
2 Trials |
|
2 Trials |  |
19 News |  |
- || locnartecan (PEN-866) - Tarveda Therap, National Cancer Institute / Bethesda
Trial completion date, Trial primary completion date, Metastases: PEN-866 in Patients With Advanced Solid Malignancies (clinicaltrials.gov) - Feb 16, 2022
P1/2, N=340, Recruiting, Sponsor: Tarveda Therapeutics
Trial completion date: Jun 2022 --> Jun 2023 | Trial primary completion date: Dec 2021 --> Jan 2023
- | locnartecan (PEN-866) - Tarveda Therap, National Cancer Institute / Bethesda
New P1/2 trial, Combination therapy: Vincristine and Temozolomide in Combination With PEN-866 for Adolescents and Young Adults With Relapsed or Refractory Solid Tumors (clinicaltrials.gov) - May 17, 2021
P1/2, N=64, Not yet recruiting, Sponsor: National Cancer Institute (NCI)
- PEN-866 / Tarveda Therapeutics
[VIRTUAL] Pen-866, a miniature drug conjugate of a heat shock protein 90 (HSP90) ligand linked to SN38 for patients with advanced solid malignancies: Phase I and expansion cohort results. (Poster Board 245) - Apr 29, 2020 - Abstract #ASCO2020ASCO_1466;
P1/2
PEN-866 will be evaluated in Phase 2a expansion cohorts enrolling multiple solid tumors (NCT03221400). Research Funding: Tarveda Therapeutics, Inc.
- PEN-866 / Tarveda Therapeutics
[VIRTUAL] Characterization of PEN-866, a Heat Shock Protein 90 (HSP90) binding conjugate of SN-38, in patient plasma and tumors from the first in human study (Virtual Meeting: All Session Times Are U.S. EDT) - Apr 13, 2020 - Abstract #AACRI2020AACR-I_156;
PEN-866 has an extended plasma half-life in patients with advanced solid malignancies and showed good stability in circulation with limited plasma exposure of the payload SN-38. Analysis of tumor biopsies up to 6 days after dosing demonstrated significant accumulation and extended exposures of PEN-866 and SN-38 within the tumor tissue that exceed plasma exposures.
- || PEN-866 / Tarveda Therapeutics
M&A: #TarvedaTherapeutics and #SciClonePharmaceuticals International Establish Licensing Agreement for #PEN866 in Greater China https://t.co/ORR5i7b8IQ (Twitter) - Mar 20, 2020
- ||| locnartecan (PEN-866) - Tarveda Therap, National Cancer Institute / Bethesda
Enrollment change, Metastases: PEN-866 in Patients With Advanced Solid Malignancies (clinicaltrials.gov) - Feb 28, 2020
P1/2, N=260, Recruiting, Sponsor: Tarveda Therapeutics
Analysis of tumor biopsies up to 6 days after dosing demonstrated significant accumulation and extended exposures of PEN-866 and SN-38 within the tumor tissue that exceed plasma exposures. N=150 --> 260
- PEN-866 / Tarveda Therapeutics
First in human phase I/IIa study of PEN-866, a heat shock protein 90 (HSP90) ligand – SN38 conjugate for patients with advanced solid tumours: Phase I results (Poster Area (Hall 4)) - Sep 11, 2019 - Abstract #ESMO2019ESMO_1484;
P1/2
PEN-866 will be evaluated in phase 2a expansion cohorts (NCT03221400). Clinical trial identification: NCT03221400 July 18, 2017.
- | locnartecan (PEN-866) - Tarveda Therap, National Cancer Institute / Bethesda
Trial completion date, Trial primary completion date, Metastases: PEN-866 in Patients With Advanced Solid Malignancies (clinicaltrials.gov) - Aug 29, 2019
P1/2, N=150, Recruiting, Sponsor: Tarveda Therapeutics
Clinical trial identification: NCT03221400 July 18, 2017. Trial completion date: Jun 2020 --> Jun 2022 | Trial primary completion date: Dec 2019 --> Dec 2021
- |||||| PEN-866 / Tarveda Therapeutics
Clinical: Dr. Heske highlighting the actively recruiting PEN866 trial for Ewing’s sarcoma and Osteosarcoma patients NCT03221400 @NIHClinicalCntr @NCIResearchCtr https://t.co/H5V7l0TAwh (Twitter) - Jun 5, 2019
P1/2
- ||||| locnartecan (PEN-866) - Tarveda Therap, National Cancer Institute / Bethesda
New P1/2 trial, Metastases: PEN-866 in Patients With Advanced Solid Malignancies (clinicaltrials.gov) - Jul 18, 2017
P1/2, N=150, Recruiting, Sponsor: Tarveda Therapeutics